Home | Business News | Browse by Publication | B | Biotech Business

RXI PHARMACEUTICALS/MASS. MEDICAL SCHOOL GET RESEARCH GRANT.

Article Excerpt
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), has announced that the company's proposed research collaboration with the University of Massachusetts Medical School (UMMS) has been selected to share in the first round of Cooperative Research Grants by the Massachusetts Life Sciences Center ("MLSC").

The MLSC awarded the grant to contribute funding to a proposed collaboration between UMMS and RXi Pharmaceuticals for the development of orally delivered RNAi therapeutics. More specifically, the grant will fund the use of RXi's rxRNAT compounds and an oral delivery technology developed by UMMS that encapsulates the rxRNAT compounds with micron-sized particles. This technology provides for efficient oral delivery of RNAi therapeutic compounds and directs these compounds to specific cell types that are involved in inflammatory diseases.

"This highly competitive grant underwent rigorous review by the Life Sciences Center's Scientific Advisory Board and...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!